The Global Insulin Sensitizers Market Size is valued at USD 14.27 billion in 2022 and is predicted to reach USD 23.35 billion by the year 2031 at a 5.8% CAGR during the forecast period for 2023-2031.
Thiazolidinediones (TZDs) are referred to as "insulin sensitizers" and are also euglycemics, which normalize blood sugar. Type 2 diabetes mellitus (T2DM) has insulin sensitizers as its accepted underlying cause. Due to the restricted prescription or removal from the market of several licenced insulin sensitizers, such as thiazolidinediones (TZDs), due to safety concerns, there is now an unmet demand for safe and effective insulin sensitizers. Therefore, diabetic patients will greatly benefit from effective insulin sensitizers devoid of TZD-like adverse effects.
The World Health Organisation predicts that the morbidity of diabetes mellitus (DM), a noninfectious pandemic disease that affects the entire world, will continue to climb in the ensuing decades, which is anticipated to drive market growth. The rise in insulin sensitizers in the general population, which is the pervasive occurrence of obesity and metabolic syndrome, is responsible for the rise in type 2 diabetes (T2DM), which affects more than 90% of diabetic patients, which is another characteristic propelling the market growth during the forecast period.
Insulin sensitizers are a pathological condition where the target cells in the liver, skeletal muscle, and adipose tissue fail to respond to insulin adequately, impairing their ability to absorb and metabolize glucose effectively.
Competitive Landscape
Some Of The The Insulin Sensitizers Market Key Players Are:
- Eli Lilly and Company
- Novo Nordisk
- Sanofi
- Merck & Co.
- Bristol Myers Squibb
- AstraZeneca
- Boehringer Ingelheim
- Johnson & Johnson
- Takeda Pharmaceutical
Market Segmentation:
The insulin sensitizers market is segmented on the basis of the type of insulin sensitizers, indication, and distribution channel. Based on the type of insulin sensitizers, the market is segmented as thiazolidinediones (TZDs), biguanides, incretin-based indication, and others. By indication, the market is segmented into type 2 diabetes, prediabetes, and polycystic ovary syndrome (PCOS). On the basis of distribution channels includes hospital pharmacies, retail pharmacies, and online pharmacies.
Based On The Type Of Insulin Sensitizers, The Thiazolidinediones (Tzds) Segment Is Accounted As A Major Contributor In The Insulin Sensitizers Market
The thiazolidinediones (TZDs) category is expected to hold a major share of the global insulin sensitizers market in 2022. This is attributed to Thiazolidinediones (TZDs) helping to lower blood sugar by improving muscle, fat, and liver sensitivity to insulin. TZDs are referred to as "insulin sensitizers" and "euglycemics," which are medications that help bring blood sugar levels back into the normal range without increasing the danger of low blood sugar.
The Type 2 Diabetes Segment Witnessed Growth At A Rapid Rate
The type 2 diabetes category is projected to develop at a fast rate in the global insulin sensitizers market. Type 2 diabetes mellitus is a disorder that is becoming more common and is linked to numerous metabolic abnormalities. The most noticeable characteristic of type 2 diabetes and the related metabolic problems is insulin resistance. Insulin sensitizers have numerous positive effects on lipid metabolism and atherosclerotic vascular processes, in addition to their therapeutic effects on glycemic management, which is expected to drive market development during the forecast period.
In The Region, The North America Insulin Sensitizers Market Holds A Significant Revenue Share
The North America insulin sensitizers market is expected to show the highest market share in terms of revenue in the near future. Increasing clinical trials on insulin sensitizers in the region are anticipated to push the market growth. Furthermore, rising research and development for various insulin sensitizers boosts the market growth. Major Market players are focusing on competition in the market, which is one of the factors propelling the market development during the forecast period.
Insulin Sensitizers Market Report Scope:
|
Report Attribute |
Specifications |
|
Market size value in 2022 |
USD 14.27 Bn |
|
Revenue forecast in 2031 |
USD 23.35 Bn |
|
Growth rate CAGR |
CAGR of 5.8 % from 2023 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
By Type Of Insulin Sensitizers, Indication, And Distribution Channel |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Eli Lilly and Company, Novo Nordisk, Sanofi, Merck & Co., Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Takeda Pharmaceutical. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
